Gilead Sciences, a leading developer and manufacturer of antiviral agents, is known for its high efficacy and safety for the human body weakened by hepatitis C. Epclusa Generic Gilead Sciences in India is recommended for carriers of the virus with and without complications who want to achieve a result (complete elimination of the virus) for 12- weekly course of therapy. The composition of the drug includes inhibitors tested by clinical practice and numerous studies in laboratories in the USA and Europe. Testing did not reveal significant side effects, and subject to a competent diagnosis and a properly prescribed treatment regimen for HCV, the recovery statistics is more than 98%.
What is the best diagnosis for starting Epclusa treatment?
The uniqueness of the development - thanks to the precisely calculated composition and dosage of the components, has a detrimental effect on Velpanat hepatitis C of all genotypes identified today from the 1st to the 6th. The use of Epclusa according to an individual regimen is indicated for:
hepatitis C (acute and chronic) without cirrhosis and other complications caused by the destruction of healthy hepatocytes;
compensated cirrhosis of the liver;
HCV with a history of repeated relapse;
uncompensated forms of fibrosis (up to stage 4 - cirrhosis) in combination with ribavirin.
Thanks to the development of biopharmaceuticals, Gilead has made possible the treatment of previously “hopeless” patients. Moreover, the course of therapy, even with cirrhosis of the liver, is quite short - 12 weeks, and the effectiveness is 65-70%. For comparison: the course of treatment for hepatitis C with interferon is at least six months, and the result is less than 40%, interferon therapy with decompensated pathology is meaningless.
Release form and composition
The drug is available in tablets, each of which contains the optimal "set" of ingredients. The active substances are sofosbuvir 400 mg and velpatasvir100 mg. The combination of components blocks NS5B, an enzyme that is "responsible" for the self-reproduction (replication) of the virus. Preventing HCV from being able to stand up for new RNA chains, Epclusa prevents its spread through healthy tissues, giving the liver the ability to regenerate and perform its functions.
Key Benefits of Epclusa
A wide spectrum of action and maximum safety for the body are not all the advantages of the original drug. Among the advantages of Epclusa, patients and doctors note:
The comfort of the reception and the speed of treatment. It is enough to take 1 tablet per day for 3 months (in rare cases, 5-6 months) to achieve SVR without relapse.
Minimum side effects. The composition does not contain toxic substances, experimental (unverified) additives, therefore, there are no serious complications in the treatment. The maximum that may be present is nausea, dizziness, general weakness, irritability.
High efficiency. Almost 100% result is a profitable investment in your own health.
The combined form gives a lower burden on the digestive organs and the cardiovascular apparatus.
Purposeful action. The medicine does not affect healthy tissues, does not affect the vital systems, since it does not react with any sites other than those affected by the virus.
The high price of Epclusa Gilead Sciences is due to the exclusivity of the drug’s formula, but the cost of Epclusa is lower than other well-known hepatitis C treatments. Sovaldi (sofosbuvir), for example, costs $ 84,000, you will have to pay up to $ 90,000 for Harvoni drugs, and Epclusa cost less than $ 75,000 for a 12-week course.
To buy Epclusa Gilead Sciences , confirmed by certificates and with protection against fakes, just fill out the form on the website for hire. We deliver the drug from pharmacies in Germany, so we are confident in their quality and reliability.
